Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

Benzinga · 2d ago
Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $82 price target.